Abeona Therapeutics

Abeona Therapeutics Inc. (Nasdaq: ABEO) is a leading clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Dallas, US
Size (employees)
6 (est)
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Abeona Therapeutics Office Locations

Abeona Therapeutics has an office in Dallas
Dallas, US (HQ)
600 3333 Lee Pkwy

Abeona Therapeutics Data and Metrics

Abeona Therapeutics Financial Metrics

Abeona Therapeutics's revenue was reported to be $889 k in FY, 2016 which is a 15% decrease from the previous period.

Revenue (FY, 2016)

889 k

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(21.9 m)

EBIT (FY, 2016)

(23.9 m)

Market capitalization (23-Jun-2017)

241.5 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

69.1 m
Abeona Therapeutics's current market capitalization is $241.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


2 m925 k1 m889 k

Revenue growth, %


Operating expense total

5.8 m4.1 m19.6 m24.8 m


(3.8 m)(3.1 m)(18.5 m)(23.9 m)

EBIT margin, %


Net Income

4.4 m(26.8 m)(14.5 m)(21.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


424 k11.5 m40.1 m69.1 m


77 k315 k155 k

Current Assets

575 k11.6 m40.6 m69.4 m


6 k4 k350 k721 k

Total Assets

613 k16.6 m80.1 m111.1 m

Accounts Payable

863 k1.9 m875 k3.7 m

Current Liabilities

9 m2.9 m1.5 m8.3 m

Additional Paid-in Capital

251.4 m300.7 m378 m431.2 m

Retained Earnings

(266.4 m)(296.1 m)(310.6 m)(332.5 m)

Total Equity

(14.8 m)4.8 m67.7 m99.1 m

Financial Leverage

0 x3.4 x1.2 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.4 m(26.8 m)(14.5 m)(21.9 m)

Depreciation and Amortization

3 k11 k551 k825 k


174 k77 k(287 k)160 k

Accounts Payable

(1.2 m)33 k(1.2 m)2.8 m

Cash From Operating Activities

1 k(1.6 m)(10.4 m)(13 m)

Capital Expenditures

(2 k)(308 k)(519 k)

Cash From Investing Activities

(2 k)3.4 m(519 k)

Cash From Financing Activities

29 k12.7 m35.7 m42.5 m

Interest Paid

7 k7 k6 k

Free Cash Flow

(1 k)(1.6 m)(10.7 m)(13.5 m)
USDY, 2016


148.2 k

Financial Leverage

1.1 x

Abeona Therapeutics Market Value History

Abeona Therapeutics Online and Social Media Presence

Abeona Therapeutics Company Life and Culture

You may also be interested in